Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America

<table class="algorithm-group"><tr><td><table class="algorithm" id="alg5"><tr><td>(i)</td><td>Treatment of patients with M0CRPC should aim at delaying the decline of their quality of life, which is likely achieved by delaying the occurrence of metastases</td></tr><tr><td>(ii)</td><td>The adequate management of adverse events is a mainstay for preventing a therapy-driven decline in quality of life</td></tr><tr><td>(iii)</td><td>Whenever possible, the patients’ quality of life should be assessed in routine practice. This assessment should rely on validated patient-reported experience measures (PREMs) or validated patient-reported outcome measures (PROMs).</td></tr></table></td></tr></table>

<div> Recommendations regarding the management of quality of life in patients with M0CRPC.</div>

Prostate Cancer

alg5

Box 5

Box 5: Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America 

Box 5 | Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America 